Navigation Links
Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
Date:12/9/2013

RARITAN, N.J., Dec. 9, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia (CLL, N=29) or small lymphocytic lymphoma (SLL, N=2). The study met its primary endpoint of safety, with data demonstrating treatment with ibrutinib as an initial therapy was associated with adverse events (AEs) that were predominantly Grade 1 or 2 in nature.

Efficacy data were also collected and showed that 71 percent (95% CI, 52.0-85.8) of patients treated with ibrutinib achieved an objective response (defined as a complete or partial response). Although estimates of progression-free survival (PFS) and overall survival (OS) were not reached at the median follow up of 22.1 months, it is estimated that more than 95% of patients would be alive and progression-free at two years.

"This early stage study in previously untreated patients suggests a positive effect with ibrutinib in CLL and SLL," said lead author Susan O'Brien, M.D., Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. "The results of this study are encouraging given the average age, overall health and unmet needs of the typical CLL population."

Primary Endpoint: Safety

Adverse events were predominantly Grade 1 or 2 in severity, with the most frequently (greater than or equal to 25 percent) reported being diarrhea (68 percent) which was often self-limited and resolved without discontinuation of treatment. Other common mild to moderate AEs that were reported included nausea (48 percent), fatigue (32 percent), hypertension (29 percent), peripheral edema (29 percent), dizziness (26 percent), dyspepsia (26 percent) and upper resp
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
2. New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA
3. Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology
4. New Drug Application for Ibrutinib Submitted to the U.S. FDA
5. Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstroms Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
6. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
7. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
8. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
11. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
(Date:11/26/2014)... SHENZHEN, China, Nov. 26, 2014 China Nepstar ... the "Company"), a leading retail drugstore chain in China ... announced its unaudited financial results for the third quarter ... ended September 30, 2014: , Same store sales increased ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11
... 2010 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... of medical devices worldwide, today announced its participation in ... Trade Fair with Congress, to be held November 17-20, ... well over 100 countries are expected to attend this ...
... Nov. 11, 2010 Dynatronics Corporation (Nasdaq: DYNT ) ... 2010. Sales for the quarter ended September 30, 2010 ... 2009. Net income for the quarter ended September 30, 2010, was ... share) for the same quarter in the prior fiscal year. ...
Cached Medicine Technology:Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010 2Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010 3Dynatronics Announces Fiscal First Quarter Results 2Dynatronics Announces Fiscal First Quarter Results 3
(Date:11/26/2014)... November 26, 2014 One of the ... at some point in her life is choosing the ... excellent platform for ladies to purchase high quality outfits. ... bridesmaid dresses. People now can pick their suitable bridesmaid ... chic dresses always make ladies look scintillating and highlight ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Vultures have developed highly ... ingest when eating dead animals, researchers report. The ... on the faces and in the guts of 50 ... On average, the faces of the vultures had more ... in their guts, the study found. The findings ...
(Date:11/26/2014)... 2014 (HealthDay News) -- The number of emergency department visits ... 2010 to a record 136 million in 2011, according to ... findings also showed that fewer people were going to ERs ... as needing medical care within two hours of arriving at ... to the research. Sixty percent of patients arrived at ...
(Date:11/26/2014)... By Steven Reinberg ... -- New rules announced Tuesday by the U.S. Food and ... on their menus, and the rules even apply to movie ... about a third of their calories away from home, often ... FDA commissioner Dr. Margaret Hamburg said during a Monday afternoon ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Parents need ... from sports concussions, an expert warns. Parents must ... and undergo standard, Dr. David Dodick, chair of the ... the Mayo Clinic College of Medicine in Scottsdale, Ariz. ... news release. Any coach involved with teens ...
Breaking Medicine News(10 mins):Health News:Royal Blue Bridesmaid Dresses Now Are Available for Christmas at BellasDress.com 2Health News:ER Visits on the Rise, Study Reports 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
... of New Molecular Entities Drops to Historic Low ... Face Increasing Competition from ... Scientific business of Thomson,Reuters today announced the availability ... Factbook, an indispensable reference,and business planning tool for ...
... welcome to out-of-state intended parents, SAN RAMON, ... decision to allow gay couples to marry strengthens ... Bay Area (RSC), one of,the state,s leading fertility ... "California,s legalization of same-sex marriage supports RSC,s,long-held ...
... for Immigration and Naturalization ready at Passport ... ... New vaccine requirements will affect,anyone who is applying for an ... status for permanent residence. Applicants,must show proof of vaccinations against vaccine-preventable ...
... Excessive IMP-3, not found in harmless moles, may be key ... produces high levels of a protein called IMP-3, which is ... researchers report. , They said the finding may offer doctors ... type of skin cancer -- from benign moles that look ...
... The American Heart,Association announces the call for ... association,s highest honor for health and science,reporting., ... and honor the career,achievements of science, health and ... in the fight against heart disease and,stroke. This ...
... County,Place Matters Team will host a three-day meeting July ... that lead to poor health outcomes,in individuals from low-income ... cities and counties will attend. Place Matters,is a national ... Health Policy Institute and is funded by the W. ...
Cached Medicine News:Health News:Thomson Reuters Publishes CMR International's 2008 Pharmaceutical R&D Factbook, Now Available for the First Time Online 2Health News:California Supreme Court Gay-Marriage Ruling Reinforces Top Bay Area Fertility Specialists' Support for Same-Sex Couples 2Health News:USCIS Tightens Vaccination Requirements 2Health News:Protein Gives Doctors New Tool to Detect Melanoma 2Health News:Alameda County Hosts National Initiative to Reduce Health Disparities 2
... Pulsavac Wound Debridement System ... for pulsatile irrigation,and debridement. ... range of fluid pressure ... lavage to a penetrating ...
... Amsco 3085 SP Surgical Table provides state-of-the-art ... now be networked with the HERMES Control ... Stryker Endoscopy) to allow the surgeon direct ... surgeon uses either simple voice commands or ...
... The ASC 2000 is ... care table, meeting good manufacturing ... regulatory requirements. It provides electro-hydraulic ... accessories for all ambulatory surgical ...
... The hands play an important part ... traumatic impairments and rheumatic changes can cause ... developing of the finger-joint prostheses was to ... reproduce the natural function as nearly possible.,The ...
Medicine Products: